CA2395217A1 - Prostaglandin compositions and methods of treatment for male erectile dysfunction - Google Patents
Prostaglandin compositions and methods of treatment for male erectile dysfunction Download PDFInfo
- Publication number
- CA2395217A1 CA2395217A1 CA002395217A CA2395217A CA2395217A1 CA 2395217 A1 CA2395217 A1 CA 2395217A1 CA 002395217 A CA002395217 A CA 002395217A CA 2395217 A CA2395217 A CA 2395217A CA 2395217 A1 CA2395217 A1 CA 2395217A1
- Authority
- CA
- Canada
- Prior art keywords
- aliphatic
- composition
- ester
- erectile dysfunction
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 208000010228 Erectile Dysfunction Diseases 0.000 title abstract 2
- 201000001881 impotence Diseases 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 abstract 3
- 239000007853 buffer solution Substances 0.000 abstract 2
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 2
- 239000003961 penetration enhancing agent Substances 0.000 abstract 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 abstract 1
- -1 N,N-disubstituted amino Chemical group 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Abstract
The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin El composition of a semi-solid consistency. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic Cl to C8 alcohol, aliphatic C2 to C30 ester, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/480,738 US6323241B1 (en) | 2000-01-10 | 2000-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US09/480,738 | 2000-01-10 | ||
PCT/US2001/000852 WO2001051053A1 (en) | 2000-01-10 | 2001-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2395217A1 true CA2395217A1 (en) | 2001-07-19 |
CA2395217C CA2395217C (en) | 2004-10-26 |
Family
ID=23909154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002395217A Expired - Lifetime CA2395217C (en) | 2000-01-10 | 2001-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
Country Status (20)
Country | Link |
---|---|
US (1) | US6323241B1 (en) |
EP (1) | EP1255552B1 (en) |
JP (2) | JP2003519657A (en) |
KR (1) | KR100614361B1 (en) |
CN (1) | CN1394140A (en) |
AT (1) | ATE290383T1 (en) |
AU (1) | AU760576C (en) |
BE (1) | BE2014C001I2 (en) |
BR (1) | BR0107478A (en) |
CA (1) | CA2395217C (en) |
DE (1) | DE60109274T2 (en) |
ES (1) | ES2236245T3 (en) |
HK (1) | HK1047700B (en) |
HU (1) | HUP0204159A3 (en) |
IL (2) | IL150306A0 (en) |
MX (1) | MXPA02006758A (en) |
PT (1) | PT1255552E (en) |
TR (1) | TR200201769T2 (en) |
WO (1) | WO2001051053A1 (en) |
ZA (1) | ZA200205433B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056044B2 (en) | 2003-03-21 | 2015-06-16 | Nexmed Holdings, Inc. | Alprostadil and lidocaine treatment of premature ejaculation |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1002847B (en) | 1997-05-06 | 1998-01-27 | Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection | |
US6414028B1 (en) * | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20050004226A1 (en) * | 1998-12-10 | 2005-01-06 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
EA008720B1 (en) * | 1998-12-10 | 2007-06-29 | Нексмед (Холдингс), Инк. | Use of a prostaglandin-based composition for amelioration of human female sexual dysfunction |
US6693135B2 (en) * | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US7105571B2 (en) * | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US20040110843A1 (en) * | 2000-01-10 | 2004-06-10 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfunction |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20090035221A1 (en) * | 2002-01-25 | 2009-02-05 | Ramsey Sallis | Methods and Compositions for Treatment of Erectile Dysfunction |
US20090257956A1 (en) * | 2002-01-25 | 2009-10-15 | Ramsey Sallis | Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation |
DK1474143T3 (en) | 2002-01-25 | 2009-01-26 | Modular Properties Ltd | Methods and compositions for treating male erectile dysfunction |
CN1610559A (en) * | 2002-02-15 | 2005-04-27 | 奈克斯麦德控股有限公司 | Prostaglandin composition for the treatment of erectile dysfunction |
CN1674912A (en) * | 2002-09-06 | 2005-09-28 | 奈克斯麦德控股有限公司 | Methods of treatment of male erectile dysfunction |
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
US6841574B2 (en) * | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
KR20050119136A (en) * | 2003-03-21 | 2005-12-20 | 넥스메드 홀딩스 인코포레이티드 | Angiogenesis promotion by prostaglandin compositions and methods |
AU2004224413A1 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Prostaglandin compositions for the treatment of erectile dysfunction |
EP1608378A1 (en) * | 2003-04-02 | 2005-12-28 | Nexmed (Holdings), Inc. | Prostaglandin compositions and their use for the treatment of vasospasm |
US20050159985A1 (en) * | 2003-11-21 | 2005-07-21 | Bertram Carl T. | System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
US7655659B2 (en) * | 2004-08-19 | 2010-02-02 | Applied Genetics Incorporated Dermatics | Biomimetic of Evodia rutaecarpa fruit extract for amelioration of inflammation |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
CA2817417C (en) * | 2010-12-02 | 2020-12-29 | Nexmed Holdings, Inc. | Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate |
US8940794B2 (en) | 2011-04-07 | 2015-01-27 | Nexmed Holdings, Inc. | Methods and compositions for treating Raynaud's disease |
US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
BR112017015510A2 (en) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | compound of formula (i), method of treatment and / or prevention, d2 receptor agonizing method in one individual, d3 receptor antagonizing method in one individual, 5-ht1d receptor agonizing method in one individual, 5-ht1a receptor agonization in one individual, selective 5-ht1d receptor agonizing method instead of 5-ht1b receptor in one individual, 5-ht2c re-receptor selective agonizing method instead of 5-ht2a or 5 receptor -ht2b in one individual, method of 5-ht2c receptor agonization in one individual, method of providing functional antagonist activity at 5-ht2b receptor or 5-ht7 receptor, and, method of providing functional antagonist activity at adrenergic receptors in one individual |
US9657020B2 (en) | 2015-01-20 | 2017-05-23 | Xoc Pharmaceuticals, Inc. | Ergoline compounds and uses thereof |
EP3266458A1 (en) | 2016-07-05 | 2018-01-10 | Fagron B.V. | Method and composition and kit for treating erectile dysfunction |
WO2018223065A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2818855A (en) | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
BE790840A (en) | 1971-11-01 | 1973-04-30 | Upjohn Co | UNSTABLE DRUG SOLUTIONS AND THEIR PREPARATION |
US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4254145A (en) | 1978-08-16 | 1981-03-03 | American Cyanamid Company | Topical application of prostaglandin hypotensive agents |
US4311707A (en) | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
SE463851B (en) | 1988-09-02 | 1991-02-04 | Amsu Ltd | COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA |
US5242391A (en) | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
ATE173603T1 (en) | 1990-04-25 | 1998-12-15 | Vivus Inc | TREATMENT OF ERECTION FAILURE |
US5380760A (en) | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
WO1996028142A1 (en) | 1995-03-14 | 1996-09-19 | Vivus, Incorporated | Method and kit for preventing erectile dysfunction |
JP2001509480A (en) * | 1997-07-09 | 2001-07-24 | アンドロソリューションズ,インク. | Improved methods and compositions for treating male erectile dysfunction |
AU734734B2 (en) * | 1997-10-28 | 2001-06-21 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6102849A (en) | 1999-04-03 | 2000-08-15 | Hakac; John R. | Non-surgical penile prosthesis |
-
2000
- 2000-01-10 US US09/480,738 patent/US6323241B1/en not_active Expired - Lifetime
-
2001
- 2001-01-10 AU AU29349/01A patent/AU760576C/en not_active Expired
- 2001-01-10 CN CN01803447A patent/CN1394140A/en active Pending
- 2001-01-10 BR BR0107478-4A patent/BR0107478A/en not_active Application Discontinuation
- 2001-01-10 KR KR1020027008845A patent/KR100614361B1/en active IP Right Grant
- 2001-01-10 IL IL15030601A patent/IL150306A0/en active IP Right Grant
- 2001-01-10 PT PT01942300T patent/PT1255552E/en unknown
- 2001-01-10 TR TR2002/01769T patent/TR200201769T2/en unknown
- 2001-01-10 CA CA002395217A patent/CA2395217C/en not_active Expired - Lifetime
- 2001-01-10 MX MXPA02006758A patent/MXPA02006758A/en active IP Right Grant
- 2001-01-10 ES ES01942300T patent/ES2236245T3/en not_active Expired - Lifetime
- 2001-01-10 DE DE60109274T patent/DE60109274T2/en not_active Expired - Lifetime
- 2001-01-10 HU HU0204159A patent/HUP0204159A3/en active IP Right Revival
- 2001-01-10 WO PCT/US2001/000852 patent/WO2001051053A1/en active IP Right Grant
- 2001-01-10 EP EP01942300A patent/EP1255552B1/en not_active Expired - Lifetime
- 2001-01-10 AT AT01942300T patent/ATE290383T1/en active
- 2001-01-10 JP JP2001551477A patent/JP2003519657A/en active Pending
-
2002
- 2002-06-18 IL IL150306A patent/IL150306A/en unknown
- 2002-07-08 ZA ZA200205433A patent/ZA200205433B/en unknown
- 2002-12-13 HK HK02109079.3A patent/HK1047700B/en not_active IP Right Cessation
-
2007
- 2007-07-18 JP JP2007186380A patent/JP2007302690A/en active Pending
-
2014
- 2014-01-06 BE BE2014C001C patent/BE2014C001I2/fr unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056044B2 (en) | 2003-03-21 | 2015-06-16 | Nexmed Holdings, Inc. | Alprostadil and lidocaine treatment of premature ejaculation |
US9060929B2 (en) | 2003-03-21 | 2015-06-23 | Nexmed Holdings, Inc. | Alprostadil for treatment of premature ejaculation |
US9066854B2 (en) | 2003-03-21 | 2015-06-30 | Nexmed Holdings, Inc. | Alprostadil and dyclonine for treatment of premature ejaculation |
Also Published As
Publication number | Publication date |
---|---|
ATE290383T1 (en) | 2005-03-15 |
DE60109274D1 (en) | 2005-04-14 |
EP1255552B1 (en) | 2005-03-09 |
IL150306A0 (en) | 2002-12-01 |
AU760576C (en) | 2004-04-08 |
EP1255552A1 (en) | 2002-11-13 |
PT1255552E (en) | 2005-06-30 |
JP2003519657A (en) | 2003-06-24 |
DE60109274T2 (en) | 2006-02-09 |
BR0107478A (en) | 2002-09-03 |
WO2001051053A1 (en) | 2001-07-19 |
HK1047700B (en) | 2005-05-27 |
AU760576B2 (en) | 2003-05-15 |
JP2007302690A (en) | 2007-11-22 |
US6323241B1 (en) | 2001-11-27 |
CA2395217C (en) | 2004-10-26 |
TR200201769T2 (en) | 2002-11-21 |
BE2014C001I2 (en) | 2020-01-30 |
ZA200205433B (en) | 2003-11-26 |
HUP0204159A3 (en) | 2005-03-29 |
HUP0204159A2 (en) | 2003-04-28 |
IL150306A (en) | 2007-06-03 |
CN1394140A (en) | 2003-01-29 |
AU2934901A (en) | 2001-07-24 |
KR20020073498A (en) | 2002-09-26 |
HK1047700A1 (en) | 2003-03-07 |
MXPA02006758A (en) | 2008-09-12 |
KR100614361B1 (en) | 2006-08-18 |
ES2236245T3 (en) | 2005-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2395217A1 (en) | Prostaglandin compositions and methods of treatment for male erectile dysfunction | |
IL160404A0 (en) | Prostaglandin compositions and methods of treatment for male erectile dysfunction | |
CA2373821A1 (en) | Topical compositions for prostaglandin e1 delivery | |
TR200202308T2 (en) | Tropical compounds containing prostaglandin E1 | |
MXPA05009816A (en) | Compositions and methods for treatment of premature ejaculation. | |
WO2002047715A3 (en) | Compositions of peptide crystals | |
CA2296373A1 (en) | Composition and method for treating penile erectile dysfunction | |
WO2000061112A3 (en) | Solubilized pharmaceutical composition for parenteral administration | |
CA2442479A1 (en) | Topical compositions for prostaglandin e1 delivery | |
TH8733A (en) | Activated protein kinase stimulates melanin production. | |
TH8733EX (en) | Activated protein kinase stimulates melanin production. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |